Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

6(85.7%)

Phase 4

1(14.3%)

7Total

N/A(6)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07495696Completed

Possibilities of Recording Changes in Various Health Parameters by Measuring Bioimpedance With the mBCA 555 During the Use of Products From the L112 Product Range

Role: lead

NCT06910111Not ApplicableNot Yet Recruiting

CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction)

Role: lead

NCT04375696Phase 4Completed

Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects

Role: lead

NCT05038436Not ApplicableCompleted

Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption

Role: lead

NCT03452085Not ApplicableCompleted

The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II

Role: lead

NCT02682277Not ApplicableCompleted

Efficacy of Polyglucosamine Long Term Treatment

Role: lead

NCT02410785Not ApplicableCompleted

Efficacy of Polyglucosamine for Weight Loss

Role: lead

NCT02529631Not ApplicableCompleted

RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

Role: lead

All 8 trials loaded